RecruitingObesity or OverweightCardiovascular Disease
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
Eligible age
40+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
Sponsor: Hoffmann-La Roche
You may qualify if…
- ✓ Participants with BMI ≥ 27 kg/m² and established CVD
- ✓ History of at least one self-reported unsuccessful dietary effort to lose body weight
You may not qualify if…
- ✕ Known history of Type 1 diabetes mellitus
- ✕ Current or previous treatment with petrelintide or any other amylin analog
Where it's recruiting
Alabama
Anniston
California
Los Angeles · San Carlos
Florida
Boynton Beach · Port Orange
Indiana
Indianapolis
Source: ClinicalTrials.gov · NCT07843472 · last updated 2026-11-16